Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins (mp, full length CD133) and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution.
The CD133 nanodisc assembles from a mixture of full length CD133 protein in detergent, phospholipid micelles and membrane scaffold protein (MSP1D1) upon removal of the detergent.
The CD133 carries a polyhistidine tag at the C-terminus with calculated MW of 97.2 kDa and migrates as 100-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. The membrane scaffold protein (MSP1D1) has calculated MW of 24.7 kDa, and it migrates as 25 kDa under reducing (R) condition (SDS-PAGE).
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD133 Full Length, His Tag (Nanodisc) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $1400.00
Price(USD) : $5200.00
Price(USD) : $11400.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.